XD technology is a cell culture process with achievement of 5-to-15 times higher in comparison to current standard bio manufacturing processes.
It is widely applicable for multiple products including proteins, fusion proteins and antibodies and has been administered across the full spectrum of mammalian cell systems.
DSM will complete the process of development and commercial manufacturing for the products
The projects will be performed at the R&D and manufacturing sites in Groningen and at new operations in Brisbane.
DSM Biologics President Karen King said a major pharma company has chosen DSM’s services and technology for three of their leading antibody pipeline projects for different indications.
"We will apply our XD technology in combination with our technology portfolio, and manufacture from our Groningen, The Netherlands, and Brisbane, Australia facilities,"King added.